- Home
- SMBK vs GERN Comparison
SMBK vs GERN Comparison
Compare SMBK & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SMBK
- GERN
- Stock Information
- Founded
- SMBK N/A
- GERN 1990
- Country
- SMBK United States
- GERN United States
- Employees
- SMBK N/A
- GERN N/A
- Industry
- SMBK Major Banks
- GERN Biotechnology: Pharmaceutical Preparations
- Sector
- SMBK Finance
- GERN Health Care
- Exchange
- SMBK Nasdaq
- GERN Nasdaq
- Market Cap
- SMBK 602.3M
- GERN 700.6M
- IPO Year
- SMBK N/A
- GERN 1996
- Fundamental
- Price
- SMBK $36.59
- GERN $1.46
- Analyst Decision
- SMBK Buy
- GERN Buy
- Analyst Count
- SMBK 4
- GERN 8
- Target Price
- SMBK $37.25
- GERN $3.71
- AVG Volume (30 Days)
- SMBK 46.7K
- GERN 12.0M
- Earning Date
- SMBK 10-20-2025
- GERN 08-06-2025
- Dividend Yield
- SMBK 0.87%
- GERN N/A
- EPS Growth
- SMBK 62.51
- GERN N/A
- EPS
- SMBK 2.47
- GERN N/A
- Revenue
- SMBK $178,959,000.00
- GERN $164,447,000.00
- Revenue This Year
- SMBK $22.41
- GERN $159.14
- Revenue Next Year
- SMBK $10.59
- GERN $52.76
- P/E Ratio
- SMBK $14.82
- GERN N/A
- Revenue Growth
- SMBK 20.51
- GERN 11877.20
- 52 Week Low
- SMBK $26.31
- GERN $1.09
- 52 Week High
- SMBK $37.72
- GERN $4.83
- Technical
- Relative Strength Index (RSI)
- SMBK 64.46
- GERN 59.63
- Support Level
- SMBK $34.73
- GERN $1.26
- Resistance Level
- SMBK $35.96
- GERN $1.55
- Average True Range (ATR)
- SMBK 0.81
- GERN 0.09
- MACD
- SMBK 0.16
- GERN 0.02
- Stochastic Oscillator
- SMBK 94.50
- GERN 75.00
About SMBK SmartFinancial Inc.
SmartFinancial Inc operates as a bank holding company for SmartBank. It offers various banking and financial services to individuals and corporate customers. The principal business of the Bank consists of attracting deposits from the general public and investing those funds, together with funds generated from operations and from principal and interest payments on loans, mainly in commercial loans, commercial and residential real estate loans, consumer loans, and residential and commercial construction loans. The primary source of revenue is interest income from earning assets, namely loans and securities.
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.